NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Forecast, Price & News $1.49 -0.01 (-0.67%) (As of 05/26/2023 08:47 PM ET) Add Compare Share Share Today's Range$1.44▼$1.5050-Day Range$1.37▼$2.1652-Week Range$1.07▼$7.20Volume16,400 shsAverage Volume159,608 shsMarket Capitalization$3.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Salarius Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.70) to ($4.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Salarius Pharmaceuticals. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.15% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently decreased by 16.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSalarius Pharmaceuticals does not currently pay a dividend.Dividend GrowthSalarius Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRX. Previous Next 4.1 News and Social Media Coverage News SentimentSalarius Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Salarius Pharmaceuticals this week, compared to 1 article on an average week.Search Interest9 people have searched for SLRX on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows4 people have added Salarius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of Salarius Pharmaceuticals is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Salarius Pharmaceuticals are expected to grow in the coming year, from ($5.70) to ($4.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Salarius Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Salarius Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSalarius Pharmaceuticals has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Salarius Pharmaceuticals (NASDAQ:SLRX) StockSalarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.Read More Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SLRX Stock News HeadlinesMay 17, 2023 | marketwatch.comSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 16, 2023 | finance.yahoo.comSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 29, 2023 | Behind the Markets (Ad)Is This The End Of Your Retirement?Soon, the U.S. Government is going to make an announcement that could radically alter your retirement. Two of America's largest banks - Goldman Sachs and J.P. Morgan - have quietly warned their richest clients to prepare for it. The clock is ticking. Find out How to Protect Yourself from the Greatest Crisis Facing Retirees in 70 Years before it's too late.May 12, 2023 | finance.yahoo.comSalarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 11, 2023 | msn.comRecap: Salarius Pharmaceuticals Q1 EarningsMay 11, 2023 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | americanbankingnews.comSalarius Pharmaceuticals, Inc. (NASDAQ:SLRX) to Post Q1 2023 Earnings of ($1.30) Per Share, Zacks Small Cap ForecastsMay 29, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>May 9, 2023 | msn.comSalarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhoodMay 9, 2023 | finance.yahoo.comFDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing SarcomaMay 2, 2023 | uk.finance.yahoo.comSalarius Pharmaceuticals, Inc. (SLRX)May 1, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164April 24, 2023 | msn.comSalarius Pharmaceuticals (FRA:FP1) Price Target Decreased by 7.80% to 55.93April 20, 2023 | finance.yahoo.comSalarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual MeetingApril 4, 2023 | finance.yahoo.comSalarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational ConferenceApril 4, 2023 | finance.yahoo.comDiamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023April 1, 2023 | americanbankingnews.comDiamond Equity Weighs in on Salarius Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:SLRX)March 31, 2023 | americanbankingnews.comSalarius Pharmaceuticals, Inc. to Post FY2023 Earnings of ($10.27) Per Share, Diamond Equity Forecasts (NASDAQ:SLRX)March 29, 2023 | americanbankingnews.comSalarius Pharmaceuticals (NASDAQ:SLRX) Posts Quarterly Earnings Results, Misses Expectations By $0.67 EPSMarch 27, 2023 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 27, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 15, 2023 | finance.yahoo.comSalarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual MeetingMarch 7, 2023 | finance.yahoo.comSalarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone SymposiaFebruary 16, 2023 | finance.yahoo.comSalarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of TexasJanuary 27, 2023 | finance.yahoo.comSalarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development SummitJanuary 22, 2023 | morningstar.comThinking about buying stock in Salarius Pharmaceuticals, Appharvest, Ally Financial, Jaguar Health, or IONQ?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SLRX Company Calendar Last Earnings3/27/2023Today5/29/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLRX CUSIPN/A CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees16Year Founded2011Profitability EPS (Most Recent Fiscal Year)($13.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-138.54% Return on Assets-112.56% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio2.21 Sales & Book Value Annual Sales$1.84 million Price / Sales2.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book0.67Miscellaneous Outstanding Shares2,490,000Free Float2,434,000Market Cap$3.71 million OptionableNot Optionable Beta0.96 Social Links Key ExecutivesDavid J. ArthurPresident, Chief Executive Officer & DirectorMark J. RosenblumChief Financial Officer & Executive Vice PresidentNadeem Q. MirzaSenior Vice President-Clinical DevelopmentKey CompetitorsAditxtNASDAQ:ADTXAgile TherapeuticsNASDAQ:AGRXHistogenNASDAQ:HSTOFirst Wave BioPharmaNASDAQ:FWBIAmpio PharmaceuticalsNYSE:AMPEView All CompetitorsInsidersWilliam K McvicarBought 26,553 shares on 6/6/2022Total: $5,045.07 ($0.19/share)Arnold C HanishBought 28,000 shares on 6/3/2022Total: $5,040.00 ($0.18/share)Mark J RosenblumBought 28,000 shares on 5/31/2022Total: $5,040.00 ($0.18/share)View All Insider Transactions SLRX Stock - Frequently Asked Questions How have SLRX shares performed in 2023? Salarius Pharmaceuticals' stock was trading at $1.53 on January 1st, 2023. Since then, SLRX shares have decreased by 2.6% and is now trading at $1.49. View the best growth stocks for 2023 here. Are investors shorting Salarius Pharmaceuticals? Salarius Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 94,700 shares, a decrease of 16.0% from the April 30th total of 112,800 shares. Based on an average daily volume of 92,600 shares, the short-interest ratio is currently 1.0 days. Currently, 4.2% of the shares of the company are short sold. View Salarius Pharmaceuticals' Short Interest. When is Salarius Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our SLRX earnings forecast. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announced its earnings results on Monday, March, 27th. The company reported ($2.83) EPS for the quarter, missing analysts' consensus estimates of ($2.16) by $0.67. What ETF holds Salarius Pharmaceuticals' stock ? Horizon Kinetics Medical ETF holds 32,400 shares of SLRX stock, representing 0.25% of its portfolio. When did Salarius Pharmaceuticals' stock split? Salarius Pharmaceuticals's stock reverse split on Monday, October 17th 2022. The 1-25 reverse split was announced on Monday, October 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX). What is Salarius Pharmaceuticals' stock symbol? Salarius Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLRX." How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Salarius Pharmaceuticals' stock price today? One share of SLRX stock can currently be purchased for approximately $1.49. How much money does Salarius Pharmaceuticals make? Salarius Pharmaceuticals (NASDAQ:SLRX) has a market capitalization of $3.71 million and generates $1.84 million in revenue each year. The company earns $-31,610,000.00 in net income (profit) each year or ($13.72) on an earnings per share basis. How can I contact Salarius Pharmaceuticals? Salarius Pharmaceuticals' mailing address is 2450 Holcombe Blvd. Suite X, Houston TX, 77021. The official website for the company is www.salariuspharma.com. The company can be reached via phone at (832) 834-6992 or via email at jeremy@lifesciadvisors.com. This page (NASDAQ:SLRX) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.